Abstract
Targeted radionuclide therapy (TRT) is today one of the most effective methods for tumor treatment. The use of the theranostic concept allows personalized approach to the choice of treatment tactics, based on diagnostic investigation using molecular imaging methods, among which PET is the most sensitive and informative. The main theranostic isotope pairs and the corresponding radiopharmaceuticals for TRT, based on β-emitters used in clinical practice, are briefly considered, and the possibilities and limitations of the well-known agents and prospects for using new radiopharmaceuticals in TRT are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
